[go: up one dir, main page]

AU2003291689A1 - Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization - Google Patents

Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization

Info

Publication number
AU2003291689A1
AU2003291689A1 AU2003291689A AU2003291689A AU2003291689A1 AU 2003291689 A1 AU2003291689 A1 AU 2003291689A1 AU 2003291689 A AU2003291689 A AU 2003291689A AU 2003291689 A AU2003291689 A AU 2003291689A AU 2003291689 A1 AU2003291689 A1 AU 2003291689A1
Authority
AU
Australia
Prior art keywords
isomerization
prone
antibodies
pharmaceutical formulation
liquid pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003291689A
Other versions
AU2003291689A8 (en
Inventor
Aleni Flores-Nate
Supriya Gupta
Elizabet A. Kaisheva
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PDL Biopharma Inc
Original Assignee
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Design Labs Inc filed Critical Protein Design Labs Inc
Publication of AU2003291689A8 publication Critical patent/AU2003291689A8/en
Publication of AU2003291689A1 publication Critical patent/AU2003291689A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU2003291689A 2002-10-31 2003-10-31 Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization Abandoned AU2003291689A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42298002P 2002-10-31 2002-10-31
US60/422,980 2002-10-31
PCT/US2003/034950 WO2004039337A2 (en) 2002-10-31 2003-10-31 Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization

Publications (2)

Publication Number Publication Date
AU2003291689A8 AU2003291689A8 (en) 2004-05-25
AU2003291689A1 true AU2003291689A1 (en) 2004-05-25

Family

ID=32230402

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003291689A Abandoned AU2003291689A1 (en) 2002-10-31 2003-10-31 Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization

Country Status (2)

Country Link
AU (1) AU2003291689A1 (en)
WO (1) WO2004039337A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE348163T1 (en) 1998-10-23 2007-01-15 Amgen Inc THROMBOPOIETIN SUBSTITUTE
MX2007014148A (en) 2005-05-19 2008-01-11 Amgen Inc Compositions and methods for increasing the stability of antibodies.
WO2007016562A2 (en) * 2005-07-29 2007-02-08 Amgen Inc. Formulations that inhibit protein aggregation
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
WO2008048430A2 (en) * 2006-10-18 2008-04-24 Amgen Inc. Identification, quantification and conversion of succinimide in proteins
AU2007309616B2 (en) 2006-10-20 2011-10-06 Amgen Inc. Stable polypeptide formulations
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
BRPI0821474B8 (en) 2007-12-28 2021-05-25 Baxalta GmbH stable liquid pharmaceutical formulation
EP2349314B1 (en) 2008-10-21 2013-02-27 Baxter International Inc. Lyophilized recombinant vwf formulations
EP2385825B1 (en) 2008-11-07 2018-10-10 University of Connecticut Factor viii formulations
SMT202000095T1 (en) 2010-05-14 2020-03-13 Amgen Inc High concentration anti-sclerostin antibody formulations
EP3074772B1 (en) * 2013-11-29 2025-06-04 F. Hoffmann-La Roche AG Antibody selection apparatus and methods
CN115925961A (en) * 2015-05-28 2023-04-07 生物辐射实验室股份有限公司 Affinity ligands and methods relating thereto
MA48461A (en) 2017-04-28 2020-03-04 Amgen Inc EXCIPIENTS TO REDUCE THE VISCOSITY OF ANTIBODY FORMULATIONS AND FORMULATION COMPOSITIONS
US20190091298A1 (en) 2017-07-07 2019-03-28 Baxalta Incorporated Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant vwf
AU2018298233B2 (en) 2017-07-07 2025-04-24 Takeda Pharmaceutical Company Limited Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant VWF
US12251474B2 (en) 2017-09-15 2025-03-18 Amgen Inc. Process for lyophilized pharmaceutical formulations of a therapeutic protein
US20210047407A1 (en) 2018-02-08 2021-02-18 Amgen Inc. Low ph pharmaceutical antibody formulation
WO2019183290A1 (en) 2018-03-21 2019-09-26 Baxalta Incorporated Separation of vwf and vwf propeptide by chromatographic methods
WO2020028401A1 (en) 2018-07-31 2020-02-06 Amgen Inc. Pharmaceutical formulations of masked antibodies
US12128090B2 (en) 2019-02-01 2024-10-29 Takeda Pharmaceutical Company Limited Methods of prophylactic treatment using recombinant VWF (rVWF)
CR20210435A (en) 2019-02-18 2021-09-20 Lilly Co Eli Therapeutic antibody formulation
US20220401524A1 (en) 2019-09-11 2022-12-22 Takeda Pharmaceutical Company Limited Methods of treatment related to complexes of von willebrand factor and complement c1q
CA3169996A1 (en) 2020-02-04 2021-08-12 Takeda Pharmaceutical Company Limited Treatment of menorrhagia in patients with severe von willebrand disease by administration of recombinant vwf

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE434680B (en) * 1983-01-21 1984-08-06 Karl Arne Lundblad APPLICATION OF A SALT SOLUTION OF MONOCLONAL ANTIBODIES WITH RELATIVE HIGH SALT CONTENT IN BLOOD GROUP DETERMINATION
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation

Also Published As

Publication number Publication date
WO2004039337A2 (en) 2004-05-13
AU2003291689A8 (en) 2004-05-25
WO2004039337A3 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
AU2003291689A1 (en) Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
IL179250A0 (en) Stable crystal of 4-oxoquinoline compound and pharmaceutical compositions containing the same
AU2003221604A1 (en) Use of an active substance that binds to cd28 for producing a pharmaceutical composition
IL166809A0 (en) Pharmaceutical nati-tnf-alpha antibody formulation
AU2003254177A1 (en) Substituted benzanilides as modulators of the ccr5 receptor
AU2003292551A1 (en) Pharmaceutical liquid composition containing pyridone derivative
AU2003261167A1 (en) Liquid dosage compositions of stable nanoparticulate active agents
AP2110A (en) Liquid pharmaceutical formulations of palonosetron
NO20055774D0 (en) Liquid stabilized protein formulations in coated pharmaceutical containers
PL375571A1 (en) Squeeze-bottle of liquid medicine
AU2003223005A1 (en) Application device for topical administration of pharmaceutical agents
EP1539156B8 (en) Liquid dosage forms of acid labile drugs
ITMI20020189A0 (en) COMPOSITION FOR PHARMACEUTICAL OR DIETARY USE TO CONTRACT HAIR LOSS
AU2003276572A1 (en) Pharmaceutical dosage forms of biguanide-sulfonylurea combinations
AU2003276054A1 (en) Method for the production of powdered active substance formulations by means of compressible fluids
SI1475379T1 (en) Use of skopin ester derivatives for the preparation of medicines
AU2001288325A1 (en) Pharmaceutical compounds useful as modulators of endocannabinoid-mediated response
AU2003274419A1 (en) Liquid conjugates of solid pharmaceuticals
AU2002258929A1 (en) Patent application of garry tsaur for container
IL173631A0 (en) Crystal forms of 1-methyl carbapenem, processes for the preparation thereof and pharmaceutical compositions containing the same
AU2003205460A1 (en) Liquid mucoadhesive pharmaceutical composition
GB0201607D0 (en) Formulation for the administration of medicinal substances
AU2003281197A1 (en) Liquid compositions for the oral administration of lorazepam
AU2003266065A1 (en) Method of preparing pharmaceutical dosage forms containing multiple active ingredients
AU2003295093A1 (en) Methods to modulate the activity of the oestrogen receptor

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase